Journal
JOURNAL OF BIOTECHNOLOGY
Volume 240, Issue -, Pages 23-30Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jbiotec.2016.10.016
Keywords
Lentiviral vector; Production; Purification; Scale-up; Gene therapy
Categories
Funding
- NHMRC
- Women's and Children's Hospital Foundation
- Cure4CF Foundation
- MS McLeod PhD Scholarship
- MS McLeod Postdoctoral Fellowship
Ask authors/readers for more resources
Lentiviruses are becoming an increasingly popular choice of gene transfer vehicle for use in the treatment of a variety of genetic and acquired human diseases. As research progresses from basic studies into pre-clinical and clinical phases, there is a growing demand for large volumes of high purity, concentrated vector, and accordingly, the means to produce such quantities. Unlike other viral vectors, lentiviruses are difficult to produce using stable cell lines, therefore transient transfection of adherent cell lines is conventionally used, and this method has proven challenging to up-scale. Furthermore, with the required increases in the volume of vector needed for larger animal and human use, comes the need for more efficient and sophisticated supernatant purification and concentration techniques. This review presents the challenges of up-scaling lentivirus production and processing approaches, novel systems for overcoming these issues, and the quality assessments recommended for producing a clinical grade lentiviral gene therapy product. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available